RIIAaers石系seqeraRIIAaers石!Q!QPage/3Theeraoftheoryisgivingwaytoexecution:platSource:Dealroom.co;*InspiredfromBioPharmaTrend,JohnMJennings,2020withmodifications**AionLabs-TheAIrevolutioninPharma沒OWKINLindusHealth5castorNETHOLABS□cytedHealthWorkflowWorkflowAutomation喜seqeraAutomataBiosecurityBiosecurity獎(jiǎng)portalGenpaxairfnitySource:Dealroom.co&ActaPharmaceuticaSinicaB,2022.-DataasofNovember20*Notallcategoriesofthelandscapearerepresentedinthefundingfigurespresentacrossmultipledrugdevelopmentphasese.g.cancertechorchemicalsynthesiswhereVCmoneygoesandwheretherealThisimbalancehighlightsastructuraline?iciencyandastrongopportunityfortechnologiesthatcanreducerisk,time,dealroom央cusp.aiailyDataasof*thenumberofpre-seedroundsin2025isexpectedtoincreaseinthecomingmonthsduetoreportinglag.VCfundingintoEuropeantechbio&AIconcentrateincoremegaroundsinflatetdominanceofthelatter.Allocationtoclinicaltrialtechremainsconstant.maturityoftheecosystemDataasofDecember2025Numberofroundsintoremainedverystrong,pointingtofewerconcentrationoffundingintomorematurecompanies.Overall,thissignalsamaturcapitalconsolidatingaroundscaledplatformsratherthanearly-stageexperime*Comparesshareofnewstartupscreatedpercategoryintheperiod2015expandedrapidly,whilemoreestslower,incrementalgrowthsignallingashifttowardnewlayersofcapabiTechBiostack. deepull$97Meeep$93MHederaDX -$71M-————————————————oore:-$42M-————————————————APH三RISCertivity--——————————————Imagene母alphobiome—————————————————————— $25M——————————————————————————rgnSource:Dealroom.co.Source:Dealroom.co.MariaTahri(Alven)TechBioMOLECULEAIMadison,Huangpu,ChinaUKBelgiumAbbottSEHKShuttlePharmaSeqOneGEHealthcare$21bn$10mtoolsBiomarkertoolsBiomarkertoolstoolsBiomarkerdiscoveryJun2025Apr2025Oct2025Sep2025Sep2025皮HUMAinatoinatoclinithink三EnaraBioclinithinkBenevolent"basebaseimmune.沒OWKINsanofiSource:DeskresearchbyDealroom.coofnewsfromcompanywebsitesandpressreleasesappearedonFiercebiotechandBusinessWireamongothersmedia.Exemplificative,not——Partnershipsem-沒OW\QEMI/Source:DeskresearchbyDealroom.coofnewsfromcompanywebsitesandpressreleasesappearedonFiercebiotechandBusinessWireamongothersmedia.Exemplificative,notallpartnershipsincluded.dealroom.coTechbiodrugdiscoveryportfoliocompaniesSource:Dealroom.co-DataasofNovInvestorlistrankedbynumberofroundsinEuropean(inclIsrael)techbiodrugdiscoverystartupsbetween2024and2025YTDdealroom.codealroomISource:ActaPharmaceuticaSinicaB,2022dealroom.codealroom.coPage/21Source:*ChartreplicatedfromAbacum-Clinicadealroom.coIllustrativedistributionofclinicaltrialcostsbyfactor*dealroomdealroom.dealroom.co1Approval1ApprovalEvenelitechemistssynthesize~1compound/weekERPsystems,labtools,andplanningdon?ttalktoeachotherlargechemistryteams,trial-and-errorsynthesisareballooningcostsmolecules.Atthesametime,globalsupplychaininstability,andashortagepressureonorganizationstofindnewwacompounds.opportunitytorethinkhowmoleculesaredesignedandmade.Aschemistrybecomesincreasinglydigitizedandclosetheloopbetweendesignandexecutionpromidealdealdealroom.codealroom.cogrowing.”dealroom Non-dilutivefundingcanprovidecriticalcapitalespeciallyintheriskiestandearlieststagesofdeexpertswithdomainknowledgethatconductthoroughreviewsofprojects.Thus,itprovidesimportantvalidationwhichcanstrengthentheconfidenceoffutureinvestors.Bystrategicallycombiningbothdilutiveandnon-dilutivefunding,entrepreneurscanstreamlinefundraisinge?orts,whileretainingmoreadecision-making.”&BITS業(yè)bioOurmissionistofostercollaborationbetweeninvestors,andtobuildaninternationallyattractiveFrenchTechBiosectortogetherwithunifiedvoice,ensuringthattheinterestsofTechBioinnovatorsarerep